Adelaide Research & Scholarship: Search

Search

Results 1-10 of 31 (Search time: 0.002 seconds).

previous
1
2
3
4
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2007	Cetuximab for the treatment of colorectal cancer	Jonker, D.; O'Callaghan, C.; Karapetis, C.; Zalcberg, J.; Tu, D.; Au, H.; Berry, S.; Krahn, M.; Price, T.; Simes, R.; Tebbutt, N.; van Hazel, G.; Wierzbicki, R.; Langer, C.; Moore, M.
	2021	Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD	Schmoll, H.J.; Stein, A.; van Cutsem, E.; Price, T.; Hofheinz, R.D.; Nordlinger, B.; Daisne, J.F.; Janssens, J.; Brenner, B.; Reinel, H.; Hollerbach, S.; Caca, K.; Fauth, F.; Hannig, C.V.; Zalcberg, J.; Tebbutt, N.; Mauer, M.E.; Marreaud, S.; Lutz, M.P.; Haustermans, K.
	2019	Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX Trial	Tapia Rico, G.; Price, T.; Tebbutt, N.; Hardingham, J.; Lee, C.; Buizen, L.; Wilson, K.; Gebski, V.; Townsend, A.
	2014	The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17	Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
	2016	Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer	Liu, G.; Tu, D.; Lewis, M.; Cheng, D.; Sullivan, L.; Chen, Z.; Morgen, E.; Simes, J.; Price, T.; Tebbutt, N.; Shapiro, J.; Jeffery, G.; Mellor, J.; Mikeska, T.; Virk, S.; Shepherd, L.; Jonker, D.; O'Callaghan, C.; Zalcberg, J.; Karapetis, C.; et al.
	2014	Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer	Jonker, D.; Karapetis, C.; Harbison, C.; O'Callaghan, C.; Tu, D.; Simes, R.; Malone, D.; Langer, C.; Tebbutt, N.; Price, T.; Shapiro, J.; Siu, L.; Wong, R.; Bjarnason, G.; Moore, M.; Zalcberg, J.; Khambata-Ford, S.
	2004	Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer	Rao, S.; Cunningham, D.; Price, T.; Hill, M.; Ross, P.; Tebbutt, N.; Norman, A.; Oates, J.; Shellito, P.
	2015	Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature	Chan, D.; Pavlakis, N.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Segelov, E.; Rosell, R.
	2013	Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab	Price, T.; Hardingham, J.; Lee, C.; Townsend, A.; Wrin, J.; Wilson, K.; Weickhardt, A.; Simes, R.; Murone, C.; Tebbutt, N.
	2014	Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines	Ransom, D.; Wilson, K.; Fournier, M.; Simes, R.; Gebski, V.; Yip, D.; Tebbutt, N.; Karapetis, C.; Ferry, D.; Gordon, S.; Price, T.